Citation Impact
Citing Papers
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
2009 Standout
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
Prospective identification of tumorigenic breast cancer cells
2003 Standout
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
2010
Short Preoperative Treatment With Erlotinib Inhibits Tumor Cell Proliferation in Hormone Receptor–Positive Breast Cancers
2008
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130
2002 StandoutNobel
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
2008 Standout
Untangling the ErbB signalling network
2001 Standout
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
2001
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
2009 Standout
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status
2004
HER-2/neu Overexpression and Response to Oophorectomy Plus Tamoxifen Adjuvant Therapy in Estrogen Receptor-Positive Premenopausal Women With Operable Breast Cancer
2003
Molecular Markers for Predicting Response to Tamoxifen in Breast Cancer Patients
2000
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 Standout
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
2000
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
2007 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup.
2002
HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer.
2001
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer.
2003
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer
2000
Targeting hypoxia in cancer therapy
2011 Standout
Estrogen receptors and human disease
2006 Standout
Stem cells, cancer, and cancer stem cells
2001 StandoutNature
Cancer to bone: a fatal attraction
2011 Standout
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20
2011
Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
2008
The risks and benefits of hormonal replacement therapy in healthy women and in breast cancer survivors
2003
Ovarian cancer
2014 Standout
Primary Care for Survivors of Breast Cancer
2000
Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer
2002
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
2005 Standout
Epidermal Growth Factor Receptor Targeting in Cancer
2006
Enabling screening in 3D microenvironments: probing matrix and stromal effects on the morphology and proliferation of T47D breast carcinoma cells
2013
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management
2009
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer
2010
Prevention of VTE in Nonsurgical Patients
2012 Standout
The Pursuit of Optimal Outcomes in Cancer Therapy in a New Age of Rationally Designed Target-Based Anticancer Agents
2000
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Chemotherapy and the war on cancer
2005 Standout
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?
2005
Microfluidic organs-on-chips
2014 Standout
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Prevention of Venous Thromboembolism
2004 Standout
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease
2011 Standout
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Prevention of Venous Thromboembolism
2008 Standout
The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours
2006
Cyclodextrin-based pharmaceutics: past, present and future
2004 Standout
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Targeting DNA topoisomerase II in cancer chemotherapy
2009 Standout
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Infection, immunoregulation, and cancer
2011
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Preservation of Fertility in Patients with Cancer
2009 Standout
Cardiotoxicity of cytotoxic drugs
2003
Incidence and Prognostic Significance of Complete Axillary Downstaging After Primary Chemotherapy in Breast Cancer Patients With T1 to T3 Tumors and Cytologically Proven Axillary Metastatic Lymph Nodes
2002
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
2005 Standout
Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer
2005
Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer
2005
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
2003 Standout
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
2003
[Selective estrogen receptor modulators (SERM): new substances for hormone replacement therapy].
1999
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
2005
Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy
1999
Repeated observation of breast tumor subtypes in independent gene expression data sets
2003 Standout
A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
2003
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
2006 Standout
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
2000
Palladium-Catalyzed Suzuki−Miyaura Cross-Coupling Reactions Employing Dialkylbiaryl Phosphine Ligands
2008 Standout
Maintenance Therapy to Suppress Micrometastasis: The New Challenge for Adjuvant Cancer Treatment
2005
Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer
2005
Integrin α5β1 Promotes Survival of Growth-Arrested Breast Cancer Cells
2004
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
2005
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
2008 Standout
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
2007 Standout
Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors
2004
Synthesis of C-15 Vindoline Analogues by Palladium-Catalyzed Cross-Coupling Reactions
2006
HER2 as a Predictor of Therapeutic Response in Breast Cancer
2000
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.
2003
Primary Systemic Therapy of Breast Cancer
2006
Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer
2006
Works of R.K. Gregory being referenced
A randomised trial of six versus twelve courses of chemotherapy in metastatic carcinoma of the breast
1997
Variation in endometrial thickening in women with amenorrhea on tamoxifen
1998
Prognostic relavance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy
2000
True
2000
Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy
2000
The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study
1996
Studies of the Potential Utility of Ki67 as a Predictive Molecular Marker of Clinical Response in Primary Breast Cancer
2003
Clinical studies of apoptosis and proliferation in breast cancer.
1999
Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma
2002
Biologic Markers as Predictors of Clinical Outcome From Systemic Therapy for Primary Operable Breast Cancer
1999
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
2000
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
1997